While regulators are steaming ahead to accelerate clinical trial and product approvals, China's pharma industry still lacks innovation. Underlying the hot investment, multi-million deals and IPOs is a lingering reliance on 'fast-following,' regulators and pharma execs tell the DIA China meeting.
Among the many words used to describe the current Chinese pharma market, from “hot” to “crowded” to "booming", the most common is “exciting.”
After all, China’s health sector has quickly emerged from the COVID-19 pandemic and is rebounding strongly, a fact underscored by...